|
Evaluation of safety and efficacy of tebipenem pivoxil granules for pediatric in pneumonia, otitis media and sinusitis
|
|
Design
|
Postmarketing surveillance study; abstract
N= 3,540
|
|
Objective
|
To evaluate the safety and efficacy of tebipenem pivoxil granules (Orapenem® fine granules 10% for pediatric) in pediatric patients with pneumonia, otitis media, or sinusitis through postmarketing surveillance
|
|
Study Groups
|
All patients (N= 3,540)
|
|
Inclusion Criteria
|
Pediatric patients with pneumonia, otitis media, or sinusitis who received tebipenem pivoxil granules (Orapenem®) during the postmarketing surveillance period (April 2010 to March 2013).
|
|
Exclusion Criteria
|
Not specified in abstract
|
|
Methods
|
Postmarketing surveillance of oral tebipenem pivoxil granules (Orapenem® fine granules 10% for pediatric) in pediatric patients with pneumonia, otitis media, or sinusitis. Of 3,547 enrolled patients, survey forms were collected for 3,540 patients, including 3,331 in the safety analysis, 2,844 in the efficacy analysis, 2,769 in the clinical efficacy analysis, and 461 in the bacteriological efficacy analysis. Assessments included adverse drug reactions, clinical efficacy, bacterial eradication, and treatment compliance.
|
|
Duration
|
Postmarketing surveillance period: April 2010 to March 2013
|
|
Outcome Measures
|
Incidence of adverse drug reactions, overall clinical efficacy and efficacy by infection type (pneumonia, otitis media, and sinusitis), bacterial eradication rates for Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, and treatment compliance
|
|
Baseline Characteristics
|
Patients were pediatric patients with pneumonia, otitis media, or sinusitis who received tebipenem pivoxil granules. Additional baseline characteristics, including age, sex, and disease severity, were not reported in the abstract. |
|
Results
|
The overall clinical efficacy rate was 94.0% (2,604/2,769 patients), with efficacy rates of 95.6% (415/434) for pneumonia, 93.7% (1,389/1,482) for otitis media, and 93.6% (659/704) for sinusitis. Bacteriological eradication rates were 94.4% (134/142 strains) for Streptococcus pneumoniae, 92.2% (130/141 strains) for Haemophilus influenzae, and 97.8% (45/46 strains) for Moraxella catarrhalis. Treatment compliance was reported as good in 83.1% (2,767/3,331) of patients.
|
|
Adverse Events
|
Adverse drug reactions were reported in 9.97% (332/3,331) of patients, primarily gastrointestinal disorders, including diarrhea, reported in 9.52% (317/3,331). Diarrhea occurred in 313 patients (316 events), with recovery or remission reported in 94.9% (297/313) of affected patients. The authors reported that the diarrhea events were not clinically significant.
|
|
Study Author Conclusions
|
These results indicate that Orapenem® fine granules 10% for pediatric is a useful agent in pediatrics with pneumonia or otitis media, or sinusitis.
|
|
InpharmD Researcher Critique
|
This was an uncontrolled, observational postmarketing surveillance study, limiting conclusions regarding comparative efficacy. Additionally, the study evaluated the Japanese tebipenem pivoxil formulation, limiting direct applicability to the U.S.-approved tebipenem pivoxil hydrobromide formulation. Only the abstract was available in English, limiting assessment of the study methodology, patient characteristics, and potential sources of bias.
|